secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001711279-26-000008
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Krystal Biotech pre-announces 2025 VYJUVEK revenue ~$388-389M; outlines 4 product launches by 2030
--------------------------------------------------------------------------------

- Preliminary Q4 2025 VYJUVEK net revenue $106-107M; full year $388-389M.
- Cash, equivalents and investments ~$955M as of Dec 31, 2025.
- Targets 4 marketed rare-disease medicines (incl. VYJUVEK) by end of 2030, treating >10,000 patients.
- 2026 combined non-GAAP R&D and SG&A expense guidance $175-195M (excl. stock comp).
- Pipeline milestones: Phase 3 data for KB803 (ocular DEB) and KB801 (NK) in 2026; KB407 CF study enrollment starts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127926000008/0001711279-26-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127926000008/krys-20260111.htm
  HTML page:      https://secwatch.observer/filing/0001711279-26-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer